Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study-Reference-Cited by-同舟云学术

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Published:2020-02-21 Issue:11 Volume:26 Page:2487-2496
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Abida Wassim,Campbell David,Patnaik Akash,Shapiro Jeremy D.,Sautois Brieuc,Vogelzang Nicholas J.^ORCID,Voog Eric G.,Bryce Alan H.^ORCID,McDermott Ray,Ricci Francesco,Rowe Julie,Zhang Jingsong,Piulats Josep Maria,Fizazi Karim,Merseburger Axel S.,Higano Celestia S.,Krieger Laurence E.,Ryan Charles J.,Feng Felix Y.,Simmons Andrew D.^ORCID,Loehr Andrea,Despain Darrin,Dowson Melanie,Green Foad,Watkins Simon P.^ORCID,Golsorkhi Tony^ORCID,Chowdhury Simon

Funder

Clovis Oncology

Ashfield Healthcare Communications

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 298 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer;Oncogene;2024-09-13

2. Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes;Cancer Treatment Reviews;2024-09

3. Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy;JAMA Oncology;2024-08-22

4. Germline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and/or Ovarian Cancer Patients and Families;Journal of Personalized Medicine;2024-08-16

5. DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes;JCO Precision Oncology;2024-08